Stribild

**Stribild (Generic: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir)**

**Comprehensive Overview:**
Stribild is a once-daily pill used to treat HIV (Human Immunodeficiency Virus). It contains a combination of four antiretroviral drugs (ARVs) that work together to suppress viral replication and maintain viral load below the level of detection.

**Mechanism of Action:**
– **Elvitegravir:** Integrase strand transfer inhibitor that blocks viral DNA from integrating into host cells.
– **Cobicistat:** Boosts the concentration of elvitegravir in the body by inhibiting its metabolism.
– **Emtricitabine:** Nucleoside reverse transcriptase inhibitor that blocks the synthesis of viral DNA.
– **Tenofovir:** Nucleotide reverse transcriptase inhibitor that also blocks viral DNA synthesis.

**Dosage and Administration:**
– One tablet taken once daily with or without food.
– Should be taken in combination with other HIV treatments.

**Clinical Indications:**
– Indicated for the treatment of HIV-1 infection in adults and pediatric patients (12 years of age and older) who weigh at least 35 kg.

**Safety Concerns:**
– May cause common side effects such as nausea, vomiting, diarrhea, headache, and fatigue.
– Rare but serious side effects include allergic reactions, liver problems, kidney problems, and bone loss.

**Monitoring and Management:**
– Regular monitoring of viral load and immune function is essential.
– Patients should be screened for hepatitis B and C before starting Stribild therapy.
– Regular kidney and liver function tests are recommended.

**SEO-Enhanced Keywords:**
HIV treatment, antiretroviral therapy, Stribild, integrase inhibitor, nucleoside reverse transcriptase inhibitor, nucleotide reverse transcriptase inhibitor, HIV-1 infection, viral suppression, CD4 count, immune function, safety profile, monitoring, management